Royal Bank of Canada
ACTU

Royal Bank of Canada’s Actuate Therapeutics ACTU Stock Holding History

Royal Bank of Canada’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$61K Sell
22,225
-13,038
-37% -$54K ﹤0.01% 5392
2025
Q4 		$215K Buy
35,263
+22,309
+172% +$153K ﹤0.01% 4705
2025
Q3 		$86K Buy
12,954
+11,627
+876% +$84.3K ﹤0.01% 5586
2025
Q2 		$8K Sell
1,327
-17,211
-93% -$150K ﹤0.01% 6550
2025
Q1 		$126K Buy
18,538
+18,236
+6,038% +$146K ﹤0.01% 5061
2024
Q4 		$2K Sell
302
-34,998
-99% -$286K ﹤0.01% 6741
2024
Q3 		$263K Buy
+35,300
New +$279K ﹤0.01% 4600

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royal Bank of Canada's ACTU Position: Q1 2026 in Review

Royal Bank of Canada reduced its Actuate Therapeutics (ACTU) stake by 37% in Q1 2026, selling an estimated $54K and leaving 22,225 shares worth $61K. The position accounts for ﹤0.01% of the portfolio, ranked #5392.

Royal Bank of Canada first reported a position in ACTU in Q3 2024 and has held it in 7 quarters since. The position peaked at $263K in Q3 2024. 61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

  • Royal Bank of Canada held 22,225 shares of Actuate Therapeutics worth $61K as of Q1 2026.
  • Royal Bank of Canada sold 13,038 Actuate Therapeutics shares in Q1 2026, an estimated $54K.
  • Actuate Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5392 holding.
  • Royal Bank of Canada first reported a position in Actuate Therapeutics in Q3 2024 and has held it in 7 quarters since.
  • Royal Bank of Canada's Actuate Therapeutics position peaked at $263K in Q3 2024.
  • 61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.